Mathias Winkler
Overview
Explore the profile of Mathias Winkler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mayor N, Light A, Silvanto A, Cullen E, Ng P, Badreldin A, et al.
BJU Int
. 2024 Nov;
135(3):502-509.
PMID: 39548928
Background: Radical prostatectomy (RP) represents the cornerstone of surgical treatment for prostate cancer. Assessing surgical margin status intraoperatively with current techniques remains challenging due to high costs in the context...
2.
van As N, Yasar B, Griffin C, Patel J, Tree A, Ostler P, et al.
Eur Urol
. 2024 Sep;
86(6):566-576.
PMID: 39266383
Background And Objective: Randomised data on patient-reported outcomes (PROs) for stereotactic body radiotherapy (SBRT) and prostatectomy in localised prostate cancer are lacking. PACE-A compared patient-reported health-related quality of life after...
3.
Dinneen E, Almeida-Magana R, Al-Hammouri T, Fernandes I, Mayor N, Mendes L, et al.
Histopathology
. 2024 Aug;
85(5):716-726.
PMID: 39104212
Intraoperative frozen section (IFS) is used with the intention to improve functional and oncological outcomes for patients undergoing radical prostatectomy (RP). High resource requirements of IFS techniques such as NeuroSAFE...
4.
Connor M, Genie M, Dudderidge T, Wu H, Sukumar J, Beresford M, et al.
Eur Urol Oncol
. 2024 Jul;
PMID: 38972831
Background And Objective: Cytoreductive treatments for patients diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) confer incremental survival benefits over systemic therapy, but these may lead to added...
5.
Santhirasekaram A, Winkler M, Rockall A, Glocker B
Med Image Anal
. 2024 Jul;
97:103260.
PMID: 38970862
Robustness of deep learning segmentation models is crucial for their safe incorporation into clinical practice. However, these models can falter when faced with distributional changes. This challenge is evident in...
6.
Santhirasekaram A, Winkler M, Rockall A, Glocker B
Int J Comput Assist Radiol Surg
. 2024 May;
20(1):11-20.
PMID: 38740720
Purpose: Automated prostate disease classification on multi-parametric MRI has recently shown promising results with the use of convolutional neural networks (CNNs). The vision transformer (ViT) is a convolutional free architecture...
7.
Challapalli A, Barwick T, Dubash S, Inglese M, Grech-Sollars M, Kozlowski K, et al.
Molecules
. 2023 Dec;
28(24).
PMID: 38138508
Malignant transformation is characterised by aberrant phospholipid metabolism of cancers, associated with the upregulation of choline kinase alpha (CHKα). Due to the metabolic instability of choline radiotracers and the increasing...
8.
Light A, Kanthabalan A, Otieno M, Pavlou M, Omar R, Adeleke S, et al.
Eur Urol
. 2023 Oct;
85(1):35-46.
PMID: 37778954
Background: The role of multiparametric magnetic resonance imaging (MRI) for detecting recurrent prostate cancer after radiotherapy is unclear. Objective: To evaluate MRI and MRI-targeted biopsies for detecting intraprostatic cancer recurrence...
9.
Reddy D, van Son M, Peters M, Bertoncelli Tanaka M, Dudderidge T, Cullen E, et al.
J Med Econ
. 2023 Sep;
26(1):1099-1107.
PMID: 37656223
Aims: Focal therapy treats individual areas of tumour in non-metastatic prostate cancer in patients unsuitable for active surveillance. The aim of this work was to evaluate the cost-effectiveness of focal...
10.
Mayor N, Eldred-Evans D, Tam H, Sokhi H, Padhani A, Connor M, et al.
BJU Int
. 2023 Aug;
133(1):112-117.
PMID: 37591614
Objective: To compare biopsy recommendation rates and accuracy of the Prostate Imaging-Reporting and Data System, version 2 (PI-RADSv2) with the Likert scale for detection of clinically significant and insignificant prostate...